Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

Lung Cancer: First-Line Treatment of M7824 Versus Pembrolizumab

Research Question:
What is the effect of M7824 monotherapy versus pembrolizumab as 1L treatment for participants with advanced NSCLC with high PD-L1-tumor expression?

Basic Study Information

Purpose:
The study will evaluate M7824 monotherapy versus pembrolizumab as first-line treatment for participants with advanced non-small-cell lung carcinoma (NSCLC) with high PD-L1-tumor expression (PD-L1 stand for Programmed Death-Ligand 1).

Location: University of Rochester Medical Center
Study Reference #: ILUN18120

Lead Researcher (Principal Investigator)

Lead Researcher: Deborah Mulford, MD

Study Contact Information

Study Coordinator: Amy Jasek
Phone: (585) 273-1912
Email: Amy_Jasek@URMC.Rochester.edu

Additional Study Details

Return to Search